Literature DB >> 8000982

Fluoxetine and selegiline--lack of significant interaction.

C H Waters1.   

Abstract

The use of the combination of fluoxetine, an anti-depressant serotonin uptake inhibitor, and selegiline, a monoamine oxidase -B inhibitor, was reviewed in a large population of patients with Parkinson's disease. All records were reviewed from a Parkinson's disease clinic to determine how many patients were treated simultaneously with selegiline and fluoxetine. Patient characteristics, duration and dose of treatment, side effects and reasons for discontinuation were noted. Twenty-three patients received both medications at the same time. No additional side effects were noted with the combination therapy that had not already been reported with each medication alone. No serious side effects were found. In this clinic population, fluoxetine and selegiline were used in combination without major side effects, but further observation is warranted.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8000982     DOI: 10.1017/s031716710004124x

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  14 in total

1.  Depression in Parkinson's Disease.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-05       Impact factor: 3.598

Review 2.  Depression in Parkinson's disease.

Authors:  Theresa A Zesiewicz; Robert A Hauser
Journal:  Curr Psychiatry Rep       Date:  2002-02       Impact factor: 5.285

3.  The selegiline transdermal system (emsam): a therapeutic option for the treatment of major depressive disorder.

Authors:  Lois Jessen; Lawrence J Kovalick; Albert J Azzaro
Journal:  P T       Date:  2008-04

Review 4.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

Review 5.  Monoamine oxidase inhibitors. An update on drug interactions.

Authors:  M G Livingston; H M Livingston
Journal:  Drug Saf       Date:  1996-04       Impact factor: 5.606

Review 6.  Antiparkinsonian agents. Drug interactions of clinical significance.

Authors:  R F Pfeiffer
Journal:  Drug Saf       Date:  1996-05       Impact factor: 5.606

Review 7.  Drug interactions of clinical significance with selective serotonin reuptake inhibitors.

Authors:  P B Mitchell
Journal:  Drug Saf       Date:  1997-12       Impact factor: 5.606

8.  Antiparkinsonian Agents : Clinically Significant Drug Interactions and Adverse Effects, and Their Management.

Authors:  A Dalvi; B Ford
Journal:  CNS Drugs       Date:  1998-04       Impact factor: 5.749

Review 9.  The serotonin syndrome. Implicated drugs, pathophysiology and management.

Authors:  K A Sporer
Journal:  Drug Saf       Date:  1995-08       Impact factor: 5.606

Review 10.  Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.

Authors:  E H Heinonen; V Myllylä
Journal:  Drug Saf       Date:  1998-07       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.